Not provided
Not provided
Not provided
Not provided
Not provided
Organisational difficulties
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The 18-kDa translocator protein (TSPO) is a mitochondrial protein that is weakly expressed in the healthy brain. However, there is an increase in the expression of TSPO in glial tumors. It is even associated with a higher malignancy and a shorter survival of patients. Among the different TSPO ligands, the most commonly used tracers in PET imaging are [18F]DPA-714 and 18F-GE180. We hypothesize that [18F]DPA-714 PET could improve the current performance for tumor grade definition in vivo, which is a major issue for the therapeutic management of gliomas.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| [18F]DPA-714 PET | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| [18F]DPA-714 | Drug | Participant received one injection of 200 MBq of [18F]DPA-714 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Diagnostic performances of [18F]DPA-714 PET for glioma grading obtained by stereotactic biopsies of glioma | Sensitivity and specificity of [18F]DPA-714 PET using anatomopathological assessment of biopsies as gold standard | [18F]DPA-714 PET performed up to 30 days before brain surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Comparison of [18F]DPA-714 PET quantitative parameters with anatomopathological assessment of the surgery specimen | Comparison of [18F]DPA-714 PET quantitative parameters with the histological types of gliomas, with the IDH1-mutational status, and the 1p19q codeletion status | [18F]DPA-714 PET performed up to 30 days before brain surgery |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Xavier PALARD NOVELLO, Dr | Centre de lutte contre le cancer Eugène Marquis | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005910 | Glioma |
| ID | Term |
|---|---|
| D018302 | Neoplasms, Neuroepithelial |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Comparison of [18F]DPA-714 PET quantitative parameters with tumor microenvironment |
Comparison of [18F]DPA-714 PET quantitative parameters with the frequency and phenotype of tumor microenvironment different glioma-associated cells |
| [18F]DPA-714 PET performed up to 30 days before brain surgery |
| D009369 | Neoplasms |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009380 | Neoplasms, Nerve Tissue |